Currently available treatment aimed to alleviate such tissue loss, as observed in RP and AMD, is such as recombinant anti-vascular endothelial growth factor (VEGF) therapy (Jo et al., 2014). This evidence concerns the gene VEGFA and age-related macular degeneration.